Maycas Marta, McAndrews Kevin A, Sato Amy Y, Pellegrini Gretel G, Brown Drew M, Allen Matthew R, Plotkin Lilian I, Gortazar Arancha R, Esbrit Pedro, Bellido Teresita
Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain.
J Bone Miner Res. 2017 Mar;32(3):486-497. doi: 10.1002/jbmr.3007. Epub 2016 Oct 24.
There is an unmet need to understand the mechanisms underlying skeletal deterioration in diabetes mellitus (DM) and to develop therapeutic approaches to treat bone fragility in diabetic patients. We demonstrate herein that mice with type 1 DM induced by streptozotocin exhibited low bone mass, inferior mechanical and material properties, increased bone resorption, decreased bone formation, increased apoptosis of osteocytes, and increased expression of the osteocyte-derived bone formation inhibitor Sost/sclerostin. Further, short treatment of diabetic mice with parathyroid hormone related protein (PTHrP)-derived peptides corrected these changes to levels undistinguishable from non-diabetic mice. In addition, diabetic mice exhibited reduced bone formation in response to mechanical stimulation, which was corrected by treatment with the PTHrP peptides, and higher prevalence of apoptotic osteocytes, which was reduced by loading or by the PTHrP peptides alone and reversed by a combination of loading and PTHrP peptide treatment. In vitro experiments demonstrated that the PTHrP peptides or mechanical stimulation by fluid flow activated the survival kinases ERKs and induced nuclear translocation of the canonical Wnt signaling mediator β-catenin, and prevented the increase in osteocytic cell apoptosis induced by high glucose. Thus, PTHrP-derived peptides cross-talk with mechanical signaling pathways to reverse skeletal deterioration induced by DM in mice. These findings suggest a crucial role of osteocytes in the harmful effects of diabetes on bone and raise the possibility of targeting these cells as a novel approach to treat skeletal deterioration in diabetes. Moreover, our study suggests the potential therapeutic efficacy of combined pharmacological and mechanical stimuli to promote bone accrual and maintenance in diabetic subjects. © 2016 American Society for Bone and Mineral Research.
目前仍存在尚未满足的需求,即了解糖尿病(DM)患者骨骼退化的潜在机制,并开发治疗糖尿病患者骨脆性的治疗方法。我们在此证明,链脲佐菌素诱导的1型糖尿病小鼠表现出骨量低、力学和材料性能差、骨吸收增加、骨形成减少、骨细胞凋亡增加以及骨细胞衍生的骨形成抑制剂Sost/硬化蛋白的表达增加。此外,用甲状旁腺激素相关蛋白(PTHrP)衍生肽对糖尿病小鼠进行短期治疗可将这些变化纠正至与非糖尿病小鼠无法区分的水平。此外,糖尿病小鼠对机械刺激的骨形成反应降低,经PTHrP肽治疗后得到纠正,凋亡骨细胞的患病率较高,通过加载或单独使用PTHrP肽可降低该患病率,而加载和PTHrP肽联合治疗可逆转该患病率。体外实验表明,PTHrP肽或流体流动引起的机械刺激激活了存活激酶ERK,并诱导了经典Wnt信号介质β-连环蛋白的核转位,从而防止了高糖诱导的骨细胞凋亡增加。因此,PTHrP衍生肽与机械信号通路相互作用,以逆转糖尿病诱导的小鼠骨骼退化。这些发现表明骨细胞在糖尿病对骨骼的有害影响中起关键作用,并提出了将这些细胞作为治疗糖尿病骨骼退化的新方法的可能性。此外,我们的研究表明联合药物和机械刺激在促进糖尿病患者骨量积累和维持方面具有潜在的治疗效果。©2016美国骨与矿物质研究学会